STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer

J. Chen1,2,3 · Y. Liu1,2,3 · Y. Zhu1,2,3 · Y. Chen1,2,3 · J. Feng1,2,3 · T. Jiang4 · X. Zheng1,2,3 · L. Chen1,2,3 · J. Jiang1,2,3

Received: 4 September 2021 / Accepted: 28 November 2021 / Published online: 2 February 2022
© The Author(s) 2022

Abstract
Background We have previously reported significant change of epithelial to mesenchymal transition (EMT) phenotype of Eca-109 cells upon PD-L1 operation, and the cytoplasmic domain of PD-L1 played an essential role in promoting EMT of esophageal cancer cells. However, the underlying mechanism of how PD-L1 regulated EMT in esophageal cancer remained unclear.

Methods The overexpression and knockdown expression models of PD-L1 and IFIT2 were established by using lenti-virus transfection and RNAi method. Western blotting, qRT-PCR, CCK8 assay, transwell assay and wound healing assay were chosen to investigate their impact on the cells. The expression levels of IFIT2 and EMT markers in esophageal cancer tissues were examined by immunohistochemical staining. The rescue experiments were further applied to investigate the role of STAT1/IFIT2 signal pathway in the PD-L1-mediated EMT. Luciferase reporter assays were performed to examine the IFIT2 promoter activities upon knockdown expression of PD-L1 to identify the putative targeted region of IFIT2 promoter.

Results The STAT1/IFIT2 signal pathway was activated when PD-L1 was knockdown in human esophageal cancer cells. Decreased IFIT2 expression significantly increased the cellular abilities of viability, invasion and migration by using RNAi method in human esophageal cancer cells. Decreased IFIT2 expression in esophageal cancer tissues significantly correlated with EMT status, and could be used as an independent prognostic predictor for the patients. Rescue experiments in PD-L1 knockdown cells further confirmed that STAT1/IFIT2 pathway was involved in the PD-L1 mediated EMT of esophageal cancer cells. Moreover, the luciferase reporter assay also confirmed that in esophageal cancer cells, the promoter region of IFIT2 (-3K~1K) remains more active in PD-L1 knockdown expression cells compared with controls.

Conclusion Our present work reveals a novel mechanism of how PD-L1 regulates EMT of cancer cells, namely STAT1/IFIT2 signal pathway is required in PD-L1 mediated EMT in human esophageal cancer.

Keywords PD-L1 · IFIT2 · EMT · Esophageal cancer

J. Chen, Y. Liu and Y. Zhu have contributed equally to this work.

J. Chen, yisheng6@163.com
Y. Liu, liuyingtingcz@163.com
Y. Zhu, zhuylan1103@126.com
Y. Chen, chendd9098@163.com
J. Feng, sudafj92@sina.com
T. Jiang, tianweij@gmail.com
X. Zheng, zhengxiao923@163.com
L. Chen, clj_sz@163.com

1 Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu, Changzhou 213003, China
2 Jiangsu Engineering Research Center for Tumor Immunotherapy, Jiangsu, Changzhou 213003, China
3 Institute of Cell Therapy, Soochow University, Jiangsu, Changzhou 213003, China
4 Department of Neurosurgery, Soochow University, Jiangsu, Changzhou 213003, China
PD-L1, also known as B7-H1, has been widely accepted as an essential tumor marker as well as an immune therapeutic target for human cancers [1, 2]. Numerous studies have also shown that, besides its negative effect on T cell immune response, abnormal PD-L1 expression also plays an essential role in malignant transformation, such as epithelial-to-mesenchymal transition (EMT) of tumor cells in many human cancers [3]. Azuma et al. have first established the theory that PD-L1 can serve as a bidirectional regulator, the extra-cellular domain of PD-L1 can interact with its receptor PD-1 on T cells, resulting in dampening T-cell mediated anti-tumor response, and the cytoplasmic domain of PD-L1 can also trigger the cellular signaling pathways involved in the anti-apoptosis via ligation with PD-1 fusion protein [4]. Moreover, it has been demonstrated that, PD-L1 transgenic-derived keratinocytes and squamous cell carcinoma cells exhibit a marked reduction of E-cadherin, and elevated expression of the transcription factors Slug and Twist, suggesting that the over-expression of PD-L1 in keratinocytes can promote EMT and accelerate carcinogenesis [5].

We have previously reported that PD-L1 can be used as an important prognostic predictor in human esophageal cancer, and confirmed that PD-L1 can potentially contribute to the EMT of esophageal cancer cells by successfully establishing cellular models including PD-L1 knockdown expression and PD-L1 over-expression in Eca-109 cell line [6]. Moreover, we have found significant change of EMT phenotype of Eca-109 cells upon operation of PD-L1, and the cytoplasmic domain of PD-L1 molecule plays a decisive role in promoting EMT of esophageal cancer cells [6]. However, the detailed molecular mechanism of how PD-L1 regulates EMT of cancer cells still remains largely unexplored. Fei et al. have reported that, over-expression of PD-L1 in nasopharyngeal cancer cells can prominently activate the EMT via PI3K/AKT signaling pathway, conferring malignancy and aggressiveness of nasopharyngeal cancer [7]. Xu et al. have demonstrated that, PD-L1 can induce EMT and enhance stemness through up-regulation of SREBP-1c in human renal cell carcinoma cells [8].

In our present study, we found that modification of PD-L1 expression could significantly regulate the STAT1/IFIT2 signaling pathway in human esophageal cancer cells. IFIT2 is an important member of IFIT family genes which are well known as a group of interferon-stimulated genes (ISGs), thus IFIT2 was also named as ISG54 [9]. IFIT2 has been confirmed to play an important role in suppressing proliferation and migration of cancer cells, and regulation of viral replication, showing anticancer effects and IFN-mediated antiviral effects [10, 11]. Herein, we further investigated the clinical significance and biological role of IFIT2 in human esophageal cancer, and confirmed that STAT1/IFIT2 pathway was involved in the PD-L1-mediated EMT of esophageal cancer cells.

**Materials and methods**

**Patients and tissue microarray preparation**

Formalin-fixed, paraffin-embedded esophageal cancer tissue samples were collected from 105 patients who underwent surgical resection between February 2005 and May 2006 in our hospital (82 males and 23 females; median age at diagnosis was 59 years). Moreover, five normal tissues from the non-malignant portion of esophagus were collected and used as controls. No patients received pre-operative chemotherapy or radiotherapy. All tumor tissues were confirmed as the esophageal squamous cell carcinoma using hematoxylin and eosin (H&E) staining after surgical resection. All these tissues were used in the construction of tissue microarray. In brief, the H&E-stained standard slides were reviewed from each section of esophageal cancer tissues, and a representative tumor region and the corresponding non-malignant portion of esophagus were collected and marked on the H&E slides, and then were sampled for the tissue microarray block which was assembled using a tissue-arraysing instrument (Beecher Instruments, Silver Springs, MD, USA). Incomplete tissue samples and several missing tissue points were excluded during the heat-induced antigen retrieval, and finally a total of 99 cases of cancer tissues were included in the present statistical analysis. The detailed clinical parameters of the patients are shown in Table 2. The tumor-node-metastasis (TNM) stages were assigned according to the American Joint Committee on Cancer criteria. Among all these 99 patients, the survival data of 86 patients were available. The present study was approved by the ethics committee of our hospital.

---

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| PD-L1        | Programmed cell death-Ligand 1 |
| ISGs         | Interferon-stimulated genes |
| EMT          | Epithelial-to-mesenchymal transition |
| OS           | Overall survival |
| IHC          | Immunohistochemistry |
| RT-PCR       | Real-time polymerase chain reaction |
| CCK-8        | Cell Counting Kit-8 |

---
**Antibodies and major reagents**

Rabbit anti-human PD-L1 monoclonal antibody (ab205921), rabbit anti-human IFIT2 polyclonal antibody (ab113112), rabbit anti-human GAPDH monoclonal antibody (ab205921), mouse anti-human STAT1 monoclonal antibody (ab3987) and mouse anti-human STAT1 (phospho Y701) monoclonal antibody (ab29045) were purchased from Abcam (Cambridge, MA, USA). Mouse anti-human E-cadherin (Cell Signaling, Danvers, MA, USA), rabbit anti-human N-cadherin and rabbit anti-human Zeb1 (Santa Cruz, Dallas, TX, USA), goat anti-mouse IgG and goat anti-rabbit IgG (Sigma, St. Louis, MO, USA) were used for Western blotting analysis. Mouse anti-human E-cadherin (MAB-0589) and Vimentin (MAB-0178) monoclonal antibodies used for the immunohistochemistry assay were purchased from Maixin Biotechnology (Fuzhou, China). The HRP-labeled goat anti mouse/rabbit secondary antibodies (K500711) were purchased from Dako (Glostrup, Denmark). The RNaseq Mini Kit was purchased from Qiagen (Valencia, CA, USA), and SYBR Green Master Mix kits were purchased from TaKaRa (Dalian, China). AG490 (S1143, Selleck) were purchased from Selleck (Shanghai, China). RPMI-1640 medium and fetal bovine serum (FBS) were purchased from Gibco (Cambrex, MD, USA).

**Cell lines and cell culture**

Human esophageal cancer cell lines, Eca-109 and TE-1 were purchased from Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences (Shanghai, China), and were cultured in RPMI1640 medium supplemented with 10% FBS in the presence of benzylpenicillin (100 U/mL), streptomycin (100 μg/mL) and 2 mM l-glutamine. The cells were incubated under standard culture conditions (5% CO₂, 37 °C). Moreover, cellular models of the knockdown expression of PD-L1, the over-expression of PD-L1, the knockdown expression of IFIT2, and the corresponding control cells, were established using lentivirus transfection as previously reported [6, 12–14].

**Immunohistochemistry and the assessment of immunostaining intensity**

Immunohistochemical staining was performed as described in our previous studies [6, 12, 15]. Briefly, the consecutive sections from the esophageal cancer tissue array block were prepared, and were dewaxed in xylene, rehydrated and graded ethanol solutions. Antigen retrieval was performed by heating the tissue sections at 100 °C for 30 min in EDTA solution (pH 9.0) or in citrate solution (pH6.0) when needed. The sections were incubated with primary antibodies against PD-L1, IFIT2, E-cadherin and Vimentin, respectively, at 4 °C overnight, followed by incubation with HRP-conjugated secondary antibody. Diaminobenzene was used as the chromogen, and hematoxylin was used as the nuclear counterstained. Finally the sections were dehydrated, cleared and mounted. Moreover, the immunostaining intensity of PD-L1, IFIT2, E-cadherin and Vimentin was evaluated as previously described [6, 12, 15, 16].

**Real-time polymerase chain reaction (RT-PCR)**

IFIT2 expression at mRNA level was examined using real-time PCR. In brief, total RNA from the cell lines was extracted using TRizol (Invitrogen), and PCR reactions were performed using the ABI 7600 system (Applied Biosystems, USA) according to the manufacturer’s instructions. Primer sequences for the detection of the reference gene (GAPDH) and the target gene (IFIT2) were synthesized and listed as follows: human GAPDH forward primer: 5ʹ-TGACTTCAACAGCGACACCCA-3ʹ, human GAPDH reverse primer: 5ʹ-CACCCTGTGCTGAGCCAAA-3ʹ, human IFIT2 forward primer: 5ʹ-GCGAAACAACTGCTCCATCT-3ʹ, human IFIT2 reverse primer: 5ʹ-CCAAGATGCAAAGCCTCA-3ʹ. The relative expression of the target gene was calculated with the 2⁻ΔΔCT method.

**Western blotting analysis**

The Western blotting analysis was used to examine the protein expression levels of PD-L1, STAT1, pSTAT1-y701, IFIT2 and GAPDH. In brief, whole cell extracts were prepared from 1 × 10⁶ cells using RIPA lysis buffer (50 mMTris/HCl pH 7.4, 150 mMNaCl, 1% Nonidet P-40, 0.25% Na-oxycholate, 1 mM EDTA and protease inhibitor cocktail). Cells were lysed on ice for 30 min, and the lysates were collected in micro-tubes and centrifuged at 12,000 rpm for 15 min at 4 °C. After centrifugation, supernatants were collected and the protein concentrations were measured using a BCA Protein Assay Kit (Beyotime, Jiangsu, China). Equal amounts of denatured proteins were subjected to SDS-PAGE and transferred onto PVDF membranes (Millipore). The membranes were blocked with 5% non-fat dry milk in TBS-T (20 mM Tris, pH 7.4, 137 mM NaCl, 0.05% Tween-20) at room temperature for 3 h, followed by incubation with primary antibodies at 4 °C overnight. Subsequently, blots were washed and incubated with anti-rabbit or anti-mouse secondary antibodies for 1 h. Finally, immuno-reactive protein bands were visualized.
using an Odyssey Scanning system (Li-Cor, Lincoln, NE, USA).

**Cellular studies of proliferation, invasion and migration**

The cell proliferation ability was examined using Cell Counting Kit-8 (CCK-8), the cell migration ability was assessed using a wound healing assay, and the cell invasive ability was examined using matrigel-coated invasion chambers as reported in our previous studies [6, 12, 13, 15].

**Luciferase reporter assay**

Luciferase reporter assays were performed to examine the IFIT2 promoter activities upon knockdown expression of PD-L1 to identify the putative targeted region of IFIT2 promoter. Six fragments of the IFIT2 promoter region were amplified and cloned into the pGL3-Basic vector (Promega, Madison, WI, USA). These constructed plasmids were named as pGL3-0.5 k-luc (500 base pairs [bp]), pGL3-1.0 k-luc (1000 bp), pGL3-1.5 k-luc (1500 bp), pGL3-2.0 k-luc (2000 bp), pGL3-2.5 k-luc (2500 bp), and pGL3-3.0 k-luc (3000 bp), according to their sequence lengths. The constructed plasmids were co-transfected with the pRL-TK plasmid into cells using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). The pRL-TK plasmid harboring Renilla luciferase was used to correct the differences in both transfection and harvest efficiencies. The activity of the firefly luciferase reporter carrying IFIT2 promoter was normalized to the Renilla luciferase activity.

**Statistical analysis**

GraphPad Prism 5.0 software package (GraphPad Software, Inc., San Diego, USA) was used in the present statistical analysis, and the Student’s t test, the Chi-square test or the Log-rank survival analysis was used where appropriate. A P value < 0.05 was considered as statistically significant.

**Fig. 1** STAT1 and IFIT2 expressions upon PD-L1 operation in human esophageal cancer cell line Eca-109. A In different cellular models including LV-NC (negative control for PD-L1 knockdown expression), LV-shPD-L1 (PD-L1 knockdown expression using RNAi method), LV-Vector-Ctrl (negative control for PD-L1 overexpression), and LV-PD-L1-OE (PD-L1 overexpression by transfecting full-length of PD-L1), the Western blotting was used to analyze PD-L1, total STAT1, pSTAT1-y701 and IFIT2 expression. B PD-L1 expression level was examined in different cellular models. C Total STAT1 was significantly up-regulated in LV-shPD-L1 cells compared with LV-NC cells (P=0.0005), but no difference was found between LV-Vector-Ctrl and LV-PD-L1-OE cells. D pSTAT1-y701 was significantly up-regulated in LV-shPD-L1 cells compared with LV-NC cells (P=0.0006), and was significantly down-regulated in LV-PD-L1-OE cells compared with LV-Vector-Ctrl cells (P<0.0001). E IFIT2 was significantly up-regulated in LV-shPD-L1 cells compared with LV-NC cells (P=0.0003), and was significantly down-regulated in LV-PD-L1-OE cells compared with LV-Vector-Ctrl cells (P=0.0035). F Immunohistochemistry results showed that the expressions of PD-L1 and IFIT2 were negatively correlated, which was found in the consecutive sections of esophageal cancer tissues.
Results

Response of STAT1/IFIT2 pathway upon PD-L1 operation in human esophageal cancer cell line Eca-109

In our previous study, we successfully established the cellular models including PD-L1 knockdown expression and PD-L1 over-expression, and further confirmed that PD-L1 positively promotes EMT of esophageal cancer cells [6]. Then, in our present study, we aimed to compare the response of STAT1/IFIT2 signaling pathway among different cellular models. As shown in Fig. 1A, in Eca-109 cells, we performed Western blotting to analyze the expressions of PD-L1, total STAT1, pSTAT1-y701 and IFIT2 in different models including LV-NC (negative control for PD-L1 knockdown expression), LV-shPD-L1 (PD-L1 knockdown expression using RNAi method), LV-Vector-Ctrl (negative control for PD-L1 over-expression), and LV-PD-L1-OE (PD-L1 over-expression by transfecting full-length of PD-L1), respectively. Figure 1B confirms that PD-L1 is down-regulated or up-regulated upon knockdown expression or over-expression of PD-L1, respectively. Figure 1C shows that total STAT1 is significantly up-regulated in LV-shPD-L1 cells in contrast to

Table 1 Correlation between IFIT2 expression and PD-L1 expression levels in human esophageal cancer tissues

| IFIT2 expression (H-score) | PD-L1 low (H-score ≤ 140) | PD-L1 high (H-score > 140) | $\chi^2$ | $P$ value |
|---------------------------|---------------------------|---------------------------|---------|-----------|
| IFIT2 low (H-score ≤ 25)  | 8                         | 9                         | 4.980   | 0.0256    |
| IFIT2 high (H-score > 25) | 61                        | 21                        |         |           |

Bold signifies $P<0.05$

Fig. 2 IFIT2 expression in human esophageal cancer tissues. A IFIT2 immunostaining could be found in the cytoplasm of cancer cells. B High IFIT2 expression could be found in adjacent normal tissue. C Survival analysis showed that, the overall survival rate of the patients with high IFIT2 expression was better than that in patients with low IFIT2 expression (HR 0.45, 95% CI 0.24–0.84, $P=0.013$). D We further used the E-cadherin in combination of Vimentin expression levels to characterize all 99 patients into EMT subgroup and non-EMT subgroup. The IFIT2 high-expression group contains 37 cases of non-EMT and 45 cases of EMT, and the IFIT2 low-expression group contains two cases of non-EMT and 15 cases of EMT.
LV-NC cells \((P = 0.0006)\), but no difference between LV-Vector-Ctrl and LV-PD-L1-OE cells. Figure 1D shows that pSTAT1-\(\gamma701\) is significantly up-regulated in LV-shPD-L1 cells in contrast to LV-NC cells \((P = 0.0008)\), and was significantly down-regulated in LV-PD-L1-OE cells in contrast to LV-Vector-Ctrl cells \((P < 0.0001)\). Figure 1E shows that IFIT2 was significantly up-regulated in LV-shPD-L1 cells in contrast to LV-NC cells \((P = 0.0003)\), and was significantly down-regulated in LV-PD-L1-OE cells in contrast to LV-Vector-Ctrl cells \((P = 0.0035)\). As shown in Fig. 1F and Table 1, we also revealed that, in human esophageal cancer tissues, the PD-L1 expression level was significantly and inversely associated with IFIT2 expression level \((\chi^2 = 4.980, P = 0.0256)\).

### Table 2 Correlation between the IFIT2 expression in human esophageal cancer tissues and patients’ clinical parameters

| Clinical parameters | Cases | IFIT2 expression level | \(\chi^2\) | \(P\) value |
|---------------------|-------|------------------------|----------|------------|
|                      |       | H-score < 50 | H-score ≥ 50 |       |
| Gender              |       |             |           |           |
| Male                | 76    | 20          | 56        | 9.349     | 0.002     |
| Female              | 23    | 14          | 9         |           |
| Age (years)         |       |             |           |           |
| ≥ 60                | 51    | 20          | 31        | 1.107     | 0.293     |
| < 60                | 48    | 14          | 34        |           |
| Tumor size          |       |             |           |           |
| < 3.5               | 35    | 14          | 21        | 0.768     | 0.381     |
| ≥ 3.5               | 64    | 20          | 44        |           |
| T stage (T)         |       |             |           |           |
| T1                  | 8     | 2           | 6         | 0.309     | 0.578     |
| T2                  | 27    | 10          | 17        |           |
| T3                  | 45    | 14          | 31        |           |
| T4                  | 19    | 8           | 11        |           |
| Lymphatic metastasis (N) | |       |           |           |
| Yes                 | 34    | 15          | 19        | 2.194     | 0.139     |
| No                  | 65    | 19          | 46        |           |
| Distant metastasis (M) |   |       |           |           |
| Yes                 | 6     | 2           | 4         | 0.003     | 0.957     |
| No                  | 93    | 32          | 61        |           |
| TNM stage           |       |             |           |           |
| I                   | 5     | 0           | 5         | 1.523     | 0.217     |
| II                  | 57    | 19          | 38        |           |
| III                 | 31    | 13          | 18        |           |
| IV                  | 6     | 2           | 4         |           |

Bold signifies \(P < 0.05\)

### Table 3 Cox model analysis for the association between the IFIT2 expression level and patient’s clinical parameters in esophageal cancer

| Variables                  | Uni-variate analysis | Multivariate analysis |
|---------------------------|----------------------|-----------------------|
|                           | HR (95% CI)          | \(P\)                 | HR (95% CI)          | \(P\)                 |
| Gender (Male: Female)     | 0.77 (0.38–1.55)     | 0.465                 | 1.24 (0.53–2.91)     | 0.620                 |
| Age (≥ 60: < 60 years)    | 0.90 (0.48–1.69)     | 0.742                 | 1.14 (0.57–2.25)     | 0.714                 |
| Tumor size (≥ 3.5 cm: < 3.5 cm) | 1.24 (0.63–2.44)     | 0.543                 | 1.00 (0.48–2.08)     | 0.992                 |
| T stage (T3–T4:T1–T2)     | 2.28 (1.08–4.80)     | 0.031                 | 2.18 (0.87–5.47)     | 0.096                 |
| Lymphatic metastasis (Yes: No) | 2.08 (1.11–3.90)     | 0.023                 | 1.89 (0.66–5.44)     | 0.239                 |
| Distant metastasis (Yes: No) | 3.00 (1.06–8.48)     | 0.039                 | 2.19 (0.67–7.18)     | 0.194                 |
| TNM stage (III + IV: I + II) | 1.88 (1.00–3.53)     | 0.050                 | 0.65 (0.19–2.18)     | 0.484                 |
| IFIT2 expression (High: Low) | 0.45 (0.24–0.84)     | 0.013                 | 0.41 (0.19–0.88)     | 0.023                 |

Bold signifies \(P < 0.05\)
Expression pattern of IFIT2 in human esophageal cancer tissues and the clinical significance

The data from our and other groups have confirmed that IFIT2 can serve as an important tumor suppressor gene, and decreased expression of IFIT2 significantly associated with cancer progression and poor prognosis of the patients [10, 12, 15]. Herein, we also aimed to examine the expression pattern and the clinical significance of IFIT2 in human esophageal cancer tissues. As shown in Fig. 2A, IFIT2 immunostaining could be found in the cytoplasm of cancer cells. Moreover, high IFIT2 expression could be found in normal tissues (Fig. 2B). As shown in Fig. 2C, the survival analysis showed that, the overall survival rate of the patients with high IFIT2 expression was better compared with the individuals with low IFIT2 expression (HR 0.45, 95% CI 0.24–0.84, \( P = 0.013 \)). As shown in Table 2, the IFIT2 expression level in esophageal cancer tissues significantly correlates with patient’s gender (\( P = 0.002 \)), but not other parameters, such as age, tumor size, T stage, lymphatic metastasis, distant metastasis or TNM stage. As shown in Table 3, the univariate analysis suggested that T stage (\( P = 0.031 \)), lymphatic metastasis (\( P = 0.023 \)), distant metastasis (\( P = 0.039 \)), TNM stage (\( P = 0.050 \)), IFIT2 expression (\( P = 0.013 \)) could be used to predict the patient’s survival, respectively. However, in the multivariate analysis, only IFIT2 expression could be used to independently predict the patient’s survival (HR 0.41, 95% CI 0.19–0.88, \( P = 0.023 \)).

As shown in Fig. 2D, if we categorized all the 99 cases of esophageal cancer patients into EMT subgroup (\( n = 60 \)) and non-EMT subgroup (\( n = 39 \)) based on the evaluation of E-cadherin as well as Vimentin expression levels. We found that in IFIT2 higher expression group, there are 37 cases of non-EMT and 45 cases of EMT, and in IFIT2 lower expression group, there are two cases of non-EMT and 15 cases of EMT, which indicates that decreased IFIT2 expression in human esophageal cancer tissues significantly associated with EMT status (\( \chi^2 = 6.562, P = 0.0104 \)).

Fig. 3 Knockdown of IFIT2 expression in human esophageal cancer cell lines. A and B In Eca-109 and TE-1 cells, after knockdown expression of IFIT2 using RNAi method, both mRNA (\( P < 0.01 \)) and protein (\( P < 0.0001 \)) levels of IFIT2 expression were significantly decreased compared with LV-NC control cells, respectively. C and F CCK8 results showed that at the timepoints of 48 h and 72 h, the cell viabilities of LV-shIFIT2 group cells were significantly increased compared with LV-NC group cells (both in Eca-109 and TE-1 cells, \( P < 0.05 \), respectively). D and G Transwell assay results showed that at the timepoint of 24 h, the cell invasion ability of LV-shIFIT2 group cells were significantly increased compared with LV-NC group cells (both in Eca-109 and TE-1 cells, \( P < 0.01 \), respectively). E and H Wound healing assay results showed that at the timepoint of 24 h, the cell invasion ability of LV-shIFIT2 group cells were significantly increased compared with LV-NC group cells (both in Eca-109 and TE-1 cells, \( P < 0.05 \), respectively).
Knockdown of IFIT2 expression in human esophageal cancer cell lines Eca-109 and TE-1

In our present study, we established the cellular model of stable knockdown IFIT2 expression in human esophageal cancer cell lines, Eca-109 and TE-1, according to the methods we have used and described in our previous report [12, 15]. As shown in Fig. 3A, in Eca-109 cells, after knockdown expression of IFIT2 using RNAi method, at both mRNA (P < 0.01) and protein (P < 0.0001) levels, IFIT2 expression significantly decreased in contrast to the LV-NC control cells. The similar results were also found in TE-1 cells (Fig. 3B). Moreover, we further investigated the cellular functions of esophageal cancer cells after IFIT2 knockdown expression. As shown in Fig. 3C, F, the CCK8 results showed that at the timepoints of 48 h and 72 h, the cell viability of LV-shIFIT2 group cells were significantly increased compared with LV-NC group cells (both in Eca-109 and TE-1 cells, P < 0.05, respectively). As shown in Fig. 3D, G, the transwell assay results showed that at the timepoint of 24 h, the cell invasion abilities of LV-shIFIT2 group cells were significantly increased compared with LV-NC group cells (both in Eca-109 and TE-1 cells, P < 0.05, respectively).

Rescue experiment in LV-shPD-L1 cells using IFIT2 knockdown expression and JAK/STAT pathway inhibition

As demonstrated in Fig. 1, we found that upon PD-L1 knockdown expression, the IFIT2 expression was significantly increased. Therefore, we aimed to study the effect of IFIT2 knockdown expression on cellular functions in LV-shPD-L1 cells in contrast to LV-NC cells. As shown in Fig. 4A, F, the CCK8 results indicated that in LV-shPD-L1 cells, the cell viability significantly increased upon IFIT2 knockdown expression in Eca-109 (P < 0.01) and TE-1 cells (P < 0.01), respectively. As shown in Fig. 4B, C, G, H, the transwell assay results indicated that in LV-shPD-L1 cells, the cell invasion ability significantly increased upon IFIT2 knockdown expression in Eca-109 (P < 0.01) and TE-1 cells (P < 0.05, respectively); meanwhile, the cell migration ability significant increased upon IFIT2 knockdown expression in Eca-109 (P < 0.01) and TE-1 cells (P < 0.01), respectively, and meanwhile, the cell migration ability of LV-shPD-L1 + siIFIT2 group still significantly lower than that in LV-NC + siIFIT2 group (Eca-109: P < 0.01, and TE-1: P < 0.01, respectively).

Moreover, to further confirm whether the up-stream signaling pathway of IFIT2, namely, JAK/STAT was involved in the regulation of the cellular function upon PD-L1 knockdown expression, we selected the JAK inhibitor AG490 to treat the esophageal cancer cell lines and compare the cellular functions as well as EMT phenotypes between LV-NC and LV-shPD-L1 groups. As shown in Fig. 5A, F, the CCK8 results indicated that in LV-shPD-L1 group, the cell viability significantly increased upon AG490 treatment in Eca-109 (P < 0.01) and TE-1 cells (P < 0.01), respectively. As shown in Fig. 5B, C, G, H, the transwell assay results indicated that in LV-shPD-L1 group, the cell invasion ability significantly increased upon AG490 treatment own expression in Eca-109 (P < 0.05) and TE-1 cells (P < 0.05), respectively. Then, the Western blotting results showed that the E-cadherin level significantly decreased upon AG490 treatment when PD-L1 was knockdown in both Eca-109 (Fig. 6A, B, P < 0.01) and TE-1 cells (Fig. 6C, D, P < 0.01), respectively, and the Vimentin level significantly increased upon AG490 treatment when PD-L1 was knockdown in both Eca-109 (Fig. 6A, B, P < 0.001) and TE-1 cells (Fig. 6C, D, P < 0.05), respectively. Therefore, in combination with the results from Fig. 1, first, we found that STAT1/IFIT2 signaling pathway was upregulated when PD-L1 was knockdown, and the rescue experiment in LV-shPD-L1 cells using IFIT2 knockdown expression and JAK/STAT pathway inhibition could reverse the changes of the cellular functions and EMT phenotypes.

PD-L1 knockdown could enhance the promoter activity of IFIT2 in esophageal cancer cells

Based on the above-mentioned results, it was suggested that STAT1/IFIT2 signaling pathway was involved in PD-L1 mediated EMT in human esophageal cancer cells. However, the detailed mechanism was still remains elusive. Therefore, it is necessary to further explore how PD-L1 reflects the IFIT2 expression in human esophageal cancer cells needs to be studied. In the present study, we further carried out the luciferase reporter assays to examine the IFIT2 promoter activity upon knockdown expression of PD-L1 to identify the putative targeted region of IFIT2 promoter. Six fragments of the IFIT2 promoter region were amplified and cloned into the pGL3-Basic vector. These constructed plasmids were named as pGL3-0.5 k-luc (500 bp), pGL3-1.0 k-luc (1000 bp), pGL3-1.5 k-luc (1500 bp), pGL3-2.0 k-luc...
Fig. 4 Rescue experiment in LV-shPD-L1 cells using IFIT2 knockdown expression. A CCK8 assay indicated that in LV-shPD-L1 cells, the cell viability significantly increased upon IFIT2 knockdown expression in Eca-109 ($P<0.01$). B and C Transwell assay indicated that in LV-shPD-L1 cells, the cell invasion ability significantly increased upon IFIT2 knockdown expression in Eca-109 ($P<0.01$), and the cell invasion ability of LV-shPD-L1 + siIFIT2 group also significantly lower than that in LV-NC + siIFIT2 group in Eca-109 cells ($P<0.01$). D and E Wound healing assay indicated that in LV-shPD-L1 cells, the cell migration ability significantly increased upon IFIT2 knockdown expression in Eca-109 cells ($P<0.01$), and the cell migration ability of LV-shPD-L1 + siIFIT2 group also significantly lower than that in LV-NC + siIFIT2 group in Eca-109 cells ($P<0.01$).

F CCK8 results indicated that in LV-shPD-L1 cells, the cell viability significantly increased upon IFIT2 knockdown expression in TE-1 cells ($P<0.01$). G and H Transwell assay results indicated that in LV-shPD-L1 cells, the cell invasion ability significantly increased upon IFIT2 knockdown expression in TE-1 cells ($P<0.05$), and the cell invasion ability of LV-shPD-L1 + siIFIT2 group also significantly lower than that in LV-NC + siIFIT2 group in TE-1 cells ($P<0.05$). I and J Wound healing assay indicated that in LV-shPD-L1 cells, the cell migration ability significantly increased upon IFIT2 knockdown expression in TE-1 cells ($P<0.01$), and the cell migration ability of LV-shPD-L1 + siIFIT2 group was also significantly lower than that in TE-1 cells ($P<0.01$)
(2000 bp), pGL3-2.5 k-luc (2500 bp), and pGL3-3.0 k-luc (3000 bp) according to their sequence lengths (Fig. 7A). Then these plasmids were co-transfected with the pRL-TK plasmid into cells. As shown in Fig. 7B–E, we found that the activity of –3000 to −1000 region of IFIT2 remains higher in the LV-shPD-L1 group compared with the LV-NC group in both Eca-109 and TE-1 cells, but not within the −1000–0 region of IFIT2 promoter (Fig. 7F, G).

Discussion

Many previous studies have confirmed that the co-stimulatory molecule PD-L1 can induce EMT and maintain cancer cell stemness in several human cancers, thus playing an important role in promoting cancer progression [3, 6, 17–22]. Moreover, Azuma et al. have established the theory that PD-L1 can serve as a bidirectional regulator, the extra-cellular domain of PD-L1 can interact with its receptor PD-1 on T cells, leading to the dampening of T cell-mediated anti-tumor response, and the cytoplasmic domain of PD-L1 can trigger the signaling pathways...
involved in the cancerous transformation upon ligation with PD-1 fusion protein [4]. However, although some reports have shown that signaling pathways, such as PI3K/AKT, are involved in the regulation of PD-L1 mediated EMT [7], the detailed molecular mechanism of how abnormal expression of PD-L1 regulates the EMT in cancer cells still remains largely unexplored.

In our previous study, we have successfully established cellular models, including PD-L1 knockdown expression, full-length PD-L1 over-expression and cytoplasmic PD-L1 truncated over-expression in human esophageal cancer cell line Eca-109 [6]. In addition, our results have illustrated that, over-expression of PD-L1 could promote EMT of Eca-109 cells and the cytoplasmic domain of PD-L1 plays a decisive role in the driving of EMT. Based on these cellular models, we subsequently aimed to study the potential mechanism of how PD-L1 regulated EMT in esophageal cancer.

It is well known that extrinsic IFNγ can up-regulate the expression of PD-L1 in tumor cells [23]. Moreover, Fernando et al. have reported that over-expression of EGFR is significantly correlated with JAK2 and PD-L1 expression in head and neck cancer (HNC) tissues in a large cohort of HNC specimens, and PD-L1 expression was induced in an EGFR- and JAK2/STAT1-dependent manner [24]. All these results describe the scenarios that the extrinsic IFNγ stimulation and the intrinsic JAK/STAT signaling pathway are involved in the up-regulation of PD-L1 expression in cancer cells. In our present study, we focused on the intrinsic regulation of downstream signal pathway upon PD-L1 intervention. First, we detected the expression levels of STAT1 and IFIT2 in different cellular models upon PD-L1 intervention in Eca-109 cells, and our results revealed that, the total STAT1 level was increased when PD-L1 knockdown, while no difference was found between PD-L1 over-expression and control cells. Interestingly, furthermore, we found that both pSTAT1-y701 and IFIT2 levels were significantly increased when PD-L1 knockdown and significantly decreased when PD-L1 was over-expressed, suggesting that STAT1/IFIT2 pathway was involved in the PD-L1-mediated regulation of biological function of esophageal cancer cells, and our following cellular studies also confirmed this speculation.

IFIT2, an important member of ISG family, is also known as ISG54, and it has been reported to play an important role in anti-viral and anti-cancer effects [25]. Like other ISG family members, IFIT2 can also be transcriptionally induced by triggering the JAK/STAT signaling pathway when different types of IFNs bind to the distinct cell surface receptors [26, 27]. Moreover, the patients with higher levels of ISGs, including IFIT2, seemed to be more sensitive to immune checkpoint immunotherapy compared with the patients with lower levels of ISG expression [28, 29]. IFIT2 has been recognized as an important tumor suppressor gene in our and other's studies, and decreased IFIT2 expression significantly increased the cellular ability of invasion and migration, and lower level of IFIT2 expression in cancer tissues can predict the poor survival of the patients [12, 15, 30]. In our present work, the cellular studies results showed that in human
esophageal cancer cells, decreased IFIT2 expression significantly increased the cellular ability of viability, invasion and migration. In addition, the retrospective study by examining the IFIT2 expression in human esophageal cancer tissues also demonstrated that decreased IFIT2 expression could be used as an independent prognostic predictor for esophageal cancer patients.

Because of STAT1 as well as IFIT2 was up-regulated in PD-L1 knockdown expression cells in contrast to control cells, we also performed the rescue experiment and further identified that either STAT1 inhibition or IFIT2 knockdown expression in LV-shPD-L1 cells could reverse the phenotypes caused by PD-L1 knockdown expression. Moreover, we also performed the luciferase reporter assay, and further confirmed that in both Eca-109 and TE-1 cells, the promoter region of IFIT2 (−3 to −1 K) remained more active in LV-shPD-L1 cells in contrast to LV-NC cells, suggesting that over-expression of PD-L1 could inhibit the promoter activity of IFIT2 and then down-regulate the IFIT2 expression, leading to the cancerous transformation and EMT. Collectively, our current findings provided a novel mechanism underlying the effects of PD-L1 on EMT of cancers, showing that STAT1/IFIT2 signaling pathway was required in PD-L1-mediated EMT in human esophageal cancer.

### Conclusion

Our present findings provided a novel mechanism underlying the effects of PD-L1 on EMT of cancer cells, showing that STAT1/IFIT2 signaling pathway was required in PD-L1-mediated EMT in human esophageal cancer.

### Author contributions

JJ contributed to the study conception and design; JC, YL, YZ, YC and LC performed the experiments; TJ, JF and XZ analyzed the data; JC and JJ contributed to manuscript drafting and supervision. All authors read and approved the final manuscript.
Funding This work was supported by grants from the National Key R&D Program (2018YFC1313400), the National Natural Science Foundation of China (317729001, 31800745, 81972869), the Key R&D Project of Science and Technology Department of Jiangsu Province (BE2016660, BE2018645), Changzhou High-Level Medical Talents Training Project (No. 2016CBZ001), High-Level Talents Project of Jiangsu Commission of Health (LGY2020034), Changzhou International Co-operation Project (CZ20210035), Changzhou Science and Technology Support Plan (Social Development) (CE202105030) and the Applied Basic Research Program of Changzhou Science and Technology Project (CJ20180061, CJ20210089).

Availability of data and materials The data sets supporting the conclusions of this article are included within the article.

Declarations

Conflict of interest The authors declare that they have no conflict of interest that would affect this paper.

Ethics approval and consent to participate Human subjects: all patients gave informed consent for participation, and the protocol for the present study was approved by the ethics committee of the Third Affiliated Hospital of Soochow University. Animals: not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Tornai M, et al. Early fatigue in cancer patients receiving PD-1/ PD-L1 checkpoint inhibitors: an insight from clinical practice. J Transl Med. 2019;17(1):376.
2. Pallacca M, Angeli D, Palombo F, Sperati F, Milella M, Goeman F, et al. Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. J Transl Med. 2019;17(1):131.
3. Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81.
4. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7–H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111(7):3635–43.
5. Cao Y, Zhang L, Ritprajak P, Tsushima F, Youngnak-Piboonratanakit P, Kamimura Y, et al. Immunoregulatory molecule B7–H1 (CD274) contributes to skin carcinogenesis. Can Res. 2011;71(14):4737–41.
6. Chen L, Xiong Y, Li J, Zheng X, Zhou Q, Turner A, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42(6):2267–80.
7. Fei Z, Deng Z, Zhou L, Li K, Xia X, Xie R. PD-L1 induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells through activation of the PI3K/AKT pathway. Oncol Res. 2019;27(7):801–7.
8. Wang Y, Wang H, Zhao Q, Xia Y, Hu X, Guo J. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol. 2015;32(8):212.
9. Fensterl V, Sen GC. The ISG56/IFIT1 gene family. J Interfer Cytokine Res. 2011;31(1):71–8.
10. Lai KC, Chang KW, Liu CJ, Kao SY, Lee TC. IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma. Mol Cancer Res. 2008;6(9):1431.
11. Chen L, Liu S, Xu F, Kong Y, Lan W, Zhang Y, et al. Inhibition of proteasome activity induces aggregation of IFIT2 in the centrosome and enhances IFIT2-induced cell apoptosis. Int J Biol Sci. 2017;13(3):383.
12. Su W, Xiao W, Chen L, Zhou Q, Zheng X, Ju J, et al. Decreased IFIT2 expression in human non-small-cell lung cancer tissues is associated with cancer progression and poor survival of the patients. Onco Targets Ther. 2019;12:8139–49.
13. Chen L, Feng J, Wu S, Xu B, Zhou Y, Wu C, et al. Decreased RIG-I expression is associated with poor prognosis and promotes cell invasion in human gastric cancer. Cancer Cell Int. 2018;18:144.
14. Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q, et al. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem. 2017;41(3):907–20.
15. Chen L, Zhai W, Zheng X, Xie Q, Zhou Q, Tao M, et al. Decreased IFIT2 expression promotes gastric cancer progression and predicts poor prognosis of the patients. Cell Physiol Biochem. 2018;45(1):15–25.
16. Liu J, Chen L, Deng H, Xu B, Li M, Zheng X, et al. Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient’s survival. Int J Clin Exp Pathol. 2014;7(10):6943–9.
17. Dongre A, Rashidiana M, Reinhardt F, Bagnato A, Keckesova Z, Poepl H, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Can Res. 2017;77(15):3982–9.
18. Raimondi C, Carpino G, Nicolazzo C, Gradilone A, Giannini W, Gelbter A, et al. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system? Oncoimmunology. 2017;6(12):e1315488.
19. Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 2016;7(13):15901–14.
20. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tullbah A, Albweigeri T, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer. 2015;14:149.
21. Funaki S, Shintani Y, Fukui E, Yamamoto Y, Kanzaki R, Ose N, et al. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma. Cancer Med. 2019;8(1):216–26.
22. Kwon MJ, Rho YS, Nam ES, Cho SJ, Park HR, Min SK, et al. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition. Hum Pathol. 2018;80:28–39.
23. Liu C, Gao AC. IFNgamma, a double-edged sword in cancer immunity and metastasis. Can Res. 2019;79(6):1032–3.

24. Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer. Can Res. 2016;76(5):1031–43.

25. Zhou X, Michal JJ, Zhang L, Ding B, Lunney JK, Liu B, et al. Interferon induced IFIT family genes in host antiviral defense. Int J Biol Sci. 2013;9(2):200–8.

26. Stawowczyk M, Van Scoy S, Kumar KP, Reich NC. The interferon stimulated gene 54 promotes apoptosis. J Biol Chem. 2011;286(9):7257–66.

27. Sen GC, Fensterl V. Crystal structure of IFIT2 (ISG54) predicts functional properties of IFITs. Cell Res. 2012;22(10):1407–9.

28. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, et al. Suppression of type I IFN signaling in tumors mediates resistance to Anti-PD-1 treatment that can be overcome by radiotherapy. Can Res. 2017;77(4):839–50.

29. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFNgamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397–404.e9.

30. Lai KC, Liu CJ, Chang KW, Lee TC. Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells. Oncogene. 2013;32(32):3686–97.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.